EPO Safety Review Will Be Closely Watched By Amgen, J&J And Roche

Roche will refine its development program for the continuous erythropoeisis receptor activator (CERA) R-744 based on an upcoming FDA advisory committee discussion of EPO safety issues, Worldwide Pharmaceuticals Head William Burns said